1. Colombo, AL, de Almeida Júnior, JN, Slavin, MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis 2017; 17: e344–e356.
Google Scholar | Crossref | Medline2. Kabir, V, Maertens, J, Kuypers, D. Fungal infections in solid organ transplantation: an update on diagnosis and treatment. Transplant Rev 2019; 33: 77–86.
Google Scholar | Crossref3. Schmiedel, Y, Zimmerli, S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly 2016; 146: w14281.
Google Scholar | Medline4. Levitz, SM . Overview of host defenses in fungal infections. Clin Infect Dis 1992; 14(Suppl. 1): S37–S42.
Google Scholar | Crossref | Medline5. Lord, AK, Vyas, JM. Host defenses to fungal pathogens. In: Rich, RR, Fleisher, TA, Shearer, WT, et al. (eds) Clinical immunology: principles and practice. 5th ed. London: Elsevier, 2019, pp. 413–424.
Google Scholar | Crossref6. Tselios, K, Gladman, DD, Sheane, BJ, et al. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). Ann Rheum Dis 2019; 78: 802–806.
Google Scholar | Crossref | Medline7. Tektonidou, MG, Wang, Z, Dasgupta, A, et al. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res 2015; 67: 1078–1085.
Google Scholar | Crossref | Medline8. Ocampo-Piraquive, V, Nieto-Aristizábal, I, Cañas, CA, et al. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol 2018; 14: 1043–1053.
Google Scholar | Crossref | Medline9. Kedves, M, Kósa, F, Kunovszki, P, et al. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. Rheumatology 2020; 59: 3443–3451.
Google Scholar | Crossref | Medline10. Azoulay, E, Russell, L, Van, de, Louw, A, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med 2020; 46: 298–314.
Google Scholar | Crossref | Medline11. Tsai, CY, Li, KJ, Hsieh, SC, et al. What’s wrong with neutrophils in lupus? Clin Exp Rheumatol 2019; 37: 684–693.
Google Scholar | Medline12. Grammatikos, AP, Tsokos, GC. Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends Mol Med 2012; 18: 101–108.
Google Scholar | Crossref | Medline13. Chen, HS, Tsai, WP, Leu, HS, et al. Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology 2007; 46: 539–544.
Google Scholar | Crossref | Medline | ISI14. Chen, D, Xie, J, Chen, H, et al. Infection in Southern Chinese Patients with systemic lupus erythematosus: spectrum, drug resistance, outcomes, and risk factors. J Rheumatol 2016; 43: 1650–1656.
Google Scholar | Crossref | Medline15. Santamaría-Alza, Y, Sánchez-Bautista, J, Fajardo-Rivero, JF, et al. Invasive fungal infections in Colombian patients with systemic lupus erythematosus. Lupus 2018; 27: 1116–1122.
Google Scholar | SAGE Journals | ISI16. Wang, LR, Barber, CE, Johnson, AS, et al. Invasive fungal disease in systemic lupus erythematosus: a systematic review of disease characteristics, risk factors, and prognosis. Semin Arthritis Rheum 2014; 44: 325–330.
Google Scholar | Crossref | Medline | ISI17. Tan, EM, Cohen, AS, Fries, JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
Google Scholar | Crossref | Medline18. Hochberg, MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
Google Scholar | Crossref19. Vandenbroucke, JP, von Elm, E, Altman, DG, et al. STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: e297.
Google Scholar | Crossref | Medline | ISI20. Winthrop, KL, Novosad, SA, Baddley, JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015; 74: 2107–2116.
Google Scholar | Crossref | Medline21. Vonk, AG, Netea, MG, van der Meer, JW, et al. Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy. Expert Opin Biol Ther 2006; 6: 891–903.
Google Scholar | Crossref | Medline22. Segal, BH . Aspergillosis. N Engl J Med 2009; 360: 1870–1884.
Google Scholar | Crossref | Medline | ISI23. Underhill, DM, Pearlman, E. Immune interactions with pathogenic and commensal fungi: a two-way street. Immunity 2015; 43: 845–858.
Google Scholar | Crossref | Medline24. Saunte, DM, Mrowietz, U, Puig, L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 2017; 177: 47–62.
Google Scholar | Crossref | Medline25. Urban, CF, Nett, JE. Neutrophil extracellular traps in fungal infection. Semin Cell Dev Biol 2019; 89: 47–57.
Google Scholar | Crossref | Medline26. Marr, KA, Carter, RA, Boeckh, M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.
Google Scholar | Crossref | Medline | ISI27. Lionakis, MS, Kontoyiannis, DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828–1838.
Google Scholar | Crossref | Medline | ISI